GENINUS (KOSDAQ: 389030) operates as a genetic testing company. It helps to commercialize technologies that analyze various genetic information. The company develops a health management service based on individuals' genetic information, applying an artificial intelligence learning algorithm to improve the accuracy of diagnosis and testing. It was founded in 2018 and is based in Seoul, South Korea.
GENINUS's Product Videos
GENINUS's Products & Differentiators
Celinus™ is a single cell RNA sequencing service. It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics. The service includes support for Single Cell Gene Expression, Single Cell Immune Profiling, Single Nucleus Gene Expression, Single Cell Multiome ATAC, and Spatial Gene Expression (Visium).
Expert Collections containing GENINUS
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
GENINUS is included in 2 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
GENINUS has filed 6 patents.
Transcription factors, Epigenetics, Genetics, Gene expression, Molecular biology
Transcription factors, Epigenetics, Genetics, Gene expression, Molecular biology
Latest GENINUS News
Nov 3, 2023
닫기 The stock prices of biotech and digital health companies, including Lunit, VUNO, JLK, Qurient, GI Innovation, and Geninus, recorded a simultaneous surge, drawing the attention of industry officials and investors. (Credit: Getty Images) On Thursday, the stock price of medical artificial intelligence (AI) company Lunit rose 17.44 percent, or 23,200 won ($17.4), from the previous day to close at 156,200 won. VUNO, which develops medical AI solutions, showed a 19.55 percent (5,700 won) increase from the previous day. JLK stocks also closed at 29,000 won, up 12.19 percent (3,150 won) from the previous day. JLK’s AI ischemic stroke (cerebral infarction) type analysis solution, JBS-01K, was recently selected as a target for health insurance coverage for innovative medical technologies in the AI field. Some of the companies whose stock prices rose sharply on the day also had one thing in common: They are participating in the Society for Immunotherapy of Cancer (SITC 2023), being held in San Diego, Calif., from Wednesday to Sunday. Founded in 1984, SITC has a membership of more than 4,600 scientists, researchers, and clinicians from 63 countries worldwide, and its annual meeting is one of the world's major cancer conferences. According to the industry, Lunit, Qurient, NKMax, GI Innovation, ABL Bio, TiUM Bioo, Eutilex, Pharmicell, Geninus, Y Biologics, Aston Sci., Genuv, and NeoImmuneTech participated in this year's event. In particular, Qurient's share price increased by 29.97 percent (1,010 won) on the day, reaching a high of 4,380 won. At this year's SITC, Qurient presented data from the phase 1 clinical trial of its oral immuno-oncology candidate adrixetinib (development name; Q702) and unveiled the clinical design for the combination with Keytruda, being co-developed with Merck (MSD). Qurient has been conducting monotherapy trials of adrixetinib in the U.S. for patients with late-stage cancers, including colorectal and pancreatic cancer. This year, the company initiated a trial of adrixetinib combined with Keytruda in the U.S. and Korea. Genomic analytics company Geninus also saw its shares climb 8.99 percent (275 won) on the day. At the SITC 2023, Geninus presents data from nonclinical efficacy trials of its cancer vaccine platform VACINUS. Geninus will file a phase 1 IND (investigational new drug) application next year. GI Innovation shares also rose 9.04 percent to 18,700 won. Following the European Society of Medical Oncology (ESMO) 2023 in Madrid, Spain, last month, GI Innovation will present the research results of its major immuno-oncology pipeline, including GI-101, GI-102, and GI-108, at SITC. Lunit, which also attended ESMO 2023, will present six poster presentations at SITC on studies that utilized its AI biomarker, Lunit SCOPE IO, to predict treatment outcomes in multiple cancers, including non-small cell lung cancer. Lunit will present a study on analyzing the distribution of tumor-infiltrating lymphocytes (TILs) to predict the treatment effectiveness of immuno-oncology therapies in patients with EGFR (epithelial growth factor receptor) mutations, the most common mutation in NSCLC, who have developed resistance after treatment with TKIs, a targeted anticancer therapy. The researchers used Lunit SCOPE IO to evaluate the distribution of TILs before and after TKI treatment in 76 patients with EGFR-mutated NSCLC. They categorized them into three immunophenotypes -- immune active, immunodeficient, and immunosuppressed. The results showed that the immune-active patients classified by Lunit SCOPE IO had a higher overall response rate (ORR, 40.0 percent vs. 7.5 percent) and progression-free survival (PFS, 4.1 months vs. 1.4 months) to immuno-oncology therapy than the immunodeficient patients. In addition, a study analyzing the correlation of TIL distribution with triple-negative breast cancer (TNBC) using Lunit SCOPE IO found that among the six molecular subtypes (gene expression patterns) of TNBC, TIL distribution was significantly higher in the immunomodulatory (IM) subtype compared to other types. "After presenting three research abstracts at SITC last year, Lunit expanded its research to a wider range of cancer types this year, resulting in six studies being accepted and presented at the conference," Lunit CEO Suh Beom-seok said. "We will continue to demonstrate the value of our AI biomarker platform, Lunit SCOPE IO, through our participation in SITC, which has emerged as the leading conference in the field of immuno-oncology, while actively pursuing various collaborations with medical stakeholders around the world."
GENINUS Frequently Asked Questions (FAQ)
When was GENINUS founded?
GENINUS was founded in 2018.
Where is GENINUS's headquarters?
GENINUS's headquarters is located at 4-5th Floor, 70, Eui-ro Munjeong-dong, KDU Tower, Seoul.
What is GENINUS's latest funding round?
GENINUS's latest funding round is IPO.
How much did GENINUS raise?
GENINUS raised a total of $20.06M.
Who are the investors of GENINUS?
Investors of GENINUS include Company K Partners, KB Investment, DAOL Investment, IMM Investment, Korea Investment Partners and 5 more.
Who are GENINUS's competitors?
Competitors of GENINUS include Foundation Medicine.
What products does GENINUS offer?
GENINUS's products include Celinus and 2 more.
Compare GENINUS to Competitors
Predict to Prevent Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development of presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention
Perthera operates as a healthcare artificial intelligence company focusing on advancing precision medicine in the oncology sector. The company offers an artificial intelligence (AI) enabled platform utilizing patient history and multi-omic testing results to match cancer patients with ranked therapy options, and accelerates clinical and therapeutic innovation. It was formerly known as Personalized Cancer Therapy. It primarily serves the healthcare industry in the oncology sector. It was founded in 2012 and is based in McLean, Virginia.
Cofactor Genomics develops a diagnostics platform helping to predict the patient's response to immunotherapy. It offers precision medicine to immunotherapy using ribonucleic acid (RNA)-expression models. The company was founded in 2008 and is based in San Francisco, California.
Tempus is a company focused on precision medicine, operating within the healthcare and artificial intelligence sectors. The company offers services that utilize artificial intelligence to provide physicians with real-time, data-driven decisions for personalized patient care and targeted therapies. It also facilitates the discovery, development, and delivery of optimized therapeutic options for patients. It was founded in 2015 and is based in Chicago, Illinois.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
SimBioSys is a technology company focused on computational oncology, operating within the healthcare and software industries. The company's main service is a biophysical simulation technology that predicts tumor responses to therapy, providing physicians with a platform for individualized treatment planning and giving patients a tool for shared decision making. SimBioSys primarily sells to the healthcare industry. It was founded in 2018 and is based in Chicago, Illinois.